{"id":7269,"date":"2024-11-05T11:03:00","date_gmt":"2024-11-05T10:03:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/alla-patienter-har-nu-slutfort-sitt-sista-besok-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\/"},"modified":"2024-11-05T11:03:00","modified_gmt":"2024-11-05T10:03:00","slug":"alla-patienter-har-nu-slutfort-sitt-sista-besok-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/alla-patienter-har-nu-slutfort-sitt-sista-besok-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\/","title":{"rendered":"Alla patienter har nu slutf\u00f6rt sitt sista bes\u00f6k i Nanexas fas I-studie med NEX-22 inom typ 2-diabetes"},"content":{"rendered":"
\n

Nanexa AB meddelar idag att samtliga patienter nu har slutf\u00f6rt bolagets fas I-studie f\u00f6r NEX-22 i typ 2-diabetes. Studien utv\u00e4rderar en l\u00e5ngverkande dep\u00e5formulering av GLP-1-analogen liraglutid med Nanexas patenterade PharmaShell\u00ae-system.<\/strong><\/p>\n<\/div>\n

\n

Alla patientbes\u00f6k p\u00e5 studiekliniken \u00e4r nu genomf\u00f6rda enligt plan. Nu \u00e5terst\u00e5r endast analys av de sist tagna blodproverna, som en del i utv\u00e4rderingen av den farmakokinetiska profilen f\u00f6r behandlingen. M\u00e5ls\u00e4ttningen \u00e4r att skapa en en-m\u00e5nads dep\u00e5formulering som f\u00f6renklar och f\u00f6rb\u00e4ttrar patienters f\u00f6ljsamhet till ordinerad behandling, vilket i f\u00f6rl\u00e4ngningen ger ett b\u00e4ttre resultat.<\/p>\n

Vi \u00e4r mycket n\u00f6jda \u00f6ver att ha genomf\u00f6rt denna viktiga studie enligt plan och ser fram emot att f\u00e5 presentera resultaten, s\u00e4ger David Westberg, VD p\u00e5 Nanexa.<\/p>\n<\/div>\n

\n

F\u00f6r mer information kontakta:<\/strong><\/p>\n

\n

David Westberg \u2013 VD, Nanexa AB (publ)\u00a0
Telefon: 0709-42 83 03
E-post:\u00a0david.westberg@nanexa.se<\/a>
www.nanexa.com<\/a><\/p>\n

Bolagets Certified Adviser \u00e4r Carnegie Investment Bank AB (publ).<\/p>\n<\/div>\n

\n

Om Nanexa AB (publ)<\/strong><\/p>\n

\n

Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n

Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

Alla patienter har nu slutf\u00f6rt sitt sista bes\u00f6k i Nanexas fas I-studie med NEX-22 inom typ 2-diabetes<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Nanexa AB meddelar idag att samtliga patienter nu har slutf\u00f6rt bolagets fas I-studie f\u00f6r NEX-22 i typ 2-diabetes. Studien utv\u00e4rderar en l\u00e5ngverkande dep\u00e5formulering av GLP-1-analogen liraglutid med Nanexas patenterade PharmaShell\u00ae-system.<\/p>\n","protected":false},"template":"","class_list":["post-7269","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nAlla patienter har nu slutf\u00f6rt sitt sista bes\u00f6k i Nanexas fas I-studie med NEX-22 inom typ 2-diabetes - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/alla-patienter-har-nu-slutfort-sitt-sista-besok-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alla patienter har nu slutf\u00f6rt sitt sista bes\u00f6k i Nanexas fas I-studie med NEX-22 inom typ 2-diabetes - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa AB meddelar idag att samtliga patienter nu har slutf\u00f6rt bolagets fas I-studie f\u00f6r NEX-22 i typ 2-diabetes. Studien utv\u00e4rderar en l\u00e5ngverkande dep\u00e5formulering av GLP-1-analogen liraglutid med Nanexas patenterade PharmaShell\u00ae-system.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/alla-patienter-har-nu-slutfort-sitt-sista-besok-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/alla-patienter-har-nu-slutfort-sitt-sista-besok-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/alla-patienter-har-nu-slutfort-sitt-sista-besok-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\\\/\",\"name\":\"Alla patienter har nu slutf\u00f6rt sitt sista bes\u00f6k i Nanexas fas I-studie med NEX-22 inom typ 2-diabetes - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2024-11-05T10:03:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/alla-patienter-har-nu-slutfort-sitt-sista-besok-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/alla-patienter-har-nu-slutfort-sitt-sista-besok-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/alla-patienter-har-nu-slutfort-sitt-sista-besok-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Alla patienter har nu slutf\u00f6rt sitt sista bes\u00f6k i Nanexas fas I-studie med NEX-22 inom typ 2-diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alla patienter har nu slutf\u00f6rt sitt sista bes\u00f6k i Nanexas fas I-studie med NEX-22 inom typ 2-diabetes - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/alla-patienter-har-nu-slutfort-sitt-sista-besok-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\/","og_locale":"sv_SE","og_type":"article","og_title":"Alla patienter har nu slutf\u00f6rt sitt sista bes\u00f6k i Nanexas fas I-studie med NEX-22 inom typ 2-diabetes - Nanexa AB","og_description":"Nanexa AB meddelar idag att samtliga patienter nu har slutf\u00f6rt bolagets fas I-studie f\u00f6r NEX-22 i typ 2-diabetes. Studien utv\u00e4rderar en l\u00e5ngverkande dep\u00e5formulering av GLP-1-analogen liraglutid med Nanexas patenterade PharmaShell\u00ae-system.","og_url":"https:\/\/nanexa.com\/mfn_news\/alla-patienter-har-nu-slutfort-sitt-sista-besok-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/alla-patienter-har-nu-slutfort-sitt-sista-besok-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\/","url":"https:\/\/nanexa.com\/mfn_news\/alla-patienter-har-nu-slutfort-sitt-sista-besok-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\/","name":"Alla patienter har nu slutf\u00f6rt sitt sista bes\u00f6k i Nanexas fas I-studie med NEX-22 inom typ 2-diabetes - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2024-11-05T10:03:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/alla-patienter-har-nu-slutfort-sitt-sista-besok-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/alla-patienter-har-nu-slutfort-sitt-sista-besok-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/alla-patienter-har-nu-slutfort-sitt-sista-besok-i-nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Alla patienter har nu slutf\u00f6rt sitt sista bes\u00f6k i Nanexas fas I-studie med NEX-22 inom typ 2-diabetes"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/7269","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=7269"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}